Literature DB >> 25813103

Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway.

Jing Xiao1, Xiao-Li Zhang1, Chensheng Fu1, Rui Han1, Weijun Chen1, Yijun Lu1, Zhibin Ye1.   

Abstract

Urate crystals activate innate immunity through Toll like receptor 4 (TLR4) activation, leading to the formation of the NACHT, LRR and PYD domains-containing protein 3 [NALP3; also known as NOD-like receptor family, pyrin domain containing 3 (NALP3) and cryopyrin] inflammasome, caspase-1 activation and interleukin (IL)-1β expression in gout. However, whether elevated serum uric acid (UA) levels are associated with the development and progression of renal diseases without renal urate crystal deposition remains unknown. In the present study, human primary renal proximal tubule epithelial cells were incubated with soluble UA (100 µg/ml) with or without the TLR4 inhibitor, TAK242 (1 µM). The gene expression and protein synthesis of TLR4, NALP3, caspase-1, IL-1β and intercellular adhesion molecule-1 (ICAM-1) were detected by real-time PCR, ELISA, western blot analysis and fluorescence-activated cell sorting (FACS), respectively. Soluble UA significantly enhanced TLR4, NALP3, caspase-1, IL-1β and ICAM-1 expression in the human primary renal proximal tubule epithelial cells. The TLR4 inhibitor, TAK242 effectively blocked the soluble UA-induced upregulation of TLR4, NALP3, caspase-1, IL-1β and ICAM-1 expression in the human primary renal proximal tubule epithelial cells. Our findings indicate that soluble UA enhances NALP3 expression, caspase-1 activation, IL-1β and ICAM-1 production in renal proximal tubule epithelial cells in a TLR4-dependent manner, suggesting the activation of innate immunity in human primary renal proximal tubule epithelial cells by soluble UA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25813103     DOI: 10.3892/ijmm.2015.2148

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  34 in total

Review 1.  Hyperuricemia and Hypertension: Links and Risks.

Authors:  Douglas J Stewart; Valerie Langlois; Damien Noone
Journal:  Integr Blood Press Control       Date:  2019-12-24

2.  Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation.

Authors:  Qiulan Lv; Daxing Xu; Jinfeng Ma; Yan Wang; Xiaomin Yang; Peng Zhao; Liang Ma; Zhiyuan Li; Wan Yang; Xiu Liu; Guanpin Yang; Shichao Xing
Journal:  Inflamm Res       Date:  2020-10-19       Impact factor: 4.575

Review 3.  Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Authors:  Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2018-02-27       Impact factor: 8.860

4.  Xanthine Oxidoreductase Inhibitors Suppress the Onset of Exercise-Induced AKI in High HPRT Activity Urat1-Uox Double Knockout Mice.

Authors:  Takuji Hosoya; Shunya Uchida; Shigeru Shibata; Naoko H Tomioka; Koji Matsumoto; Makoto Hosoyamada
Journal:  J Am Soc Nephrol       Date:  2021-11-19       Impact factor: 10.121

Review 5.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

6.  Uric acid within the "normal" range predict 9-year cardiovascular mortality in older individuals. The InCHIANTI study.

Authors:  Gloria Brombo; Francesco Bonetti; Stefano Volpato; Mario L Morieri; Ettore Napoli; Stefania Bandinelli; Antonio Cherubini; Marcello Maggio; Jack Guralnik; Luigi Ferrucci; Giovanni Zuliani
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-06-28       Impact factor: 4.222

7.  Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice.

Authors:  Annayya R Aroor; Guanghong Jia; Javad Habibi; Zhe Sun; Francisco I Ramirez-Perez; Barron Brady; Dongqing Chen; Luis A Martinez-Lemus; Camila Manrique; Ravi Nistala; Adam T Whaley-Connell; Vincent G Demarco; Gerald A Meininger; James R Sowers
Journal:  Metabolism       Date:  2017-06-21       Impact factor: 8.694

Review 8.  The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.

Authors:  Yuka Sato; Daniel I Feig; Austin G Stack; Duk-Hee Kang; Miguel A Lanaspa; A Ahsan Ejaz; L Gabriela Sánchez-Lozada; Masanari Kuwabara; Claudio Borghi; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2019-07-11       Impact factor: 28.314

Review 9.  Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage.

Authors:  Abutaleb Ahsan Ejaz; Takahiko Nakagawa; Mehmet Kanbay; Masanari Kuwabara; Ada Kumar; Fernando E Garcia Arroyo; Carlos Roncal-Jimenez; Fumihiko Sasai; Duk-Hee Kang; Thomas Jensen; Ana Andres Hernando; Bernardo Rodriguez-Iturbe; Gabriela Garcia; Dean R Tolan; Laura G Sanchez-Lozada; Miguel A Lanaspa; Richard J Johnson
Journal:  Semin Nephrol       Date:  2020-11       Impact factor: 5.299

Review 10.  Uric Acid and Hypertension: An Update With Recommendations.

Authors:  Laura G Sanchez-Lozada; Bernardo Rodriguez-Iturbe; Eric E Kelley; Takahiko Nakagawa; Magdalena Madero; Dan I Feig; Claudio Borghi; Federica Piani; Gabriel Cara-Fuentes; Petter Bjornstad; Miguel A Lanaspa; Richard J Johnson
Journal:  Am J Hypertens       Date:  2020-07-18       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.